Tesamorelin significantly reduced visceral adipose tissue ( mean change , -34 cm2 [ 95 % CI , -53 to -15 cm2 ] with tesamorelin vs 8 cm2 [ 95 % CI , -14 to 30 cm2 ] with placebo ; treatment effect , -42 cm2 [ 95 % CI , -71 to -14 cm2 ] ; P = .005 ) and liver fat ( median change in lipid to water percentage , -2.0 % [ interquartile range { IQR } , -6.4 % to 0.1 % ] with tesamorelin vs 0.9 % [ IQR , -0.6 % to 3.7 % ] with placebo ; P = .003 ) over 6 months , for a net treatment effect of -2.9 % in lipid to water percentage .